The clinical trial report, “Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2025" provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma
- Feb 21, 2025: Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
- Feb 20, 2025: Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
- Feb 14, 2025: Azer-cel Demonstrates Two Additional Complete Responses in CD19 CAR-T Phase 1b Trial with 57% Complete Response Rate
- Feb 13, 2025: Allogene Announces Publication of Response Data from Phase 1 ALPHA/ALPHA2 Trials of Allogeneic ALLO-501 in R/R LBCL in Journal of Clinical Oncology
- Feb 06, 2025: Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab, for the Treatment of Diffuse Large B-Cell Lymphoma
- Jan 29, 2025: Cargo Therapeutics To Discontinue Firce-1 Phase 2 Study of Firi-Cel; Advances Remaining Programs While Evaluating Strategic Options
- Jan 13, 2025: Verismo doses first subject in Phase I trial of SynKIR-310
- Jan 03, 2025: First Australian patient dosed in Phase 1b azer-cel clinical trial
- Dec 30, 2024: ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ DLBCL
- Dec 11, 2024: ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in DLBCL
- Dec 09, 2024: New and Updated Data for Genentech’s Fixed-Duration Columvi at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
- Dec 09, 2024: Two Data Analyses From Clinical Trials Show Epcoritamab Induces Durable Complete Reponses As Monotherapy and Combination in DLBCL
- Dec 09, 2024: New and Updated Data for Genentech’s Fixed-Duration Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
- Dec 09, 2024: Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH
- Dec 08, 2024: Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
- Dec 08, 2024: Merck’s Zilovertamab Vedotin in Combination with R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial in DLBCL
- Dec 08, 2024: Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH
- Dec 07, 2024: Nektar Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Large B-cell Lymphoma at 66th Annual ASH Meeting
- Dec 06, 2024: ADC Therapeutics to Provide Initial Data Update on Lotis-7 Clinical Trial
- Dec 06, 2024: Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL
- Dec 05, 2024: FDA Accepts Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Clinical Trial Profile Snapshots
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Disclaimer
- Source
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Co
- Roche Holding AG
- AbbVie Inc
- Gilead Sciences Inc
- AstraZeneca Plc
- Novartis AG
- Johnson & Johnson
- Pfizer Inc
- Merck & Co Inc
- Amgen Inc
